SecBot SecBot
EFFECT ·Filed Jul 13, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC9999999995-26-002261
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for any takedown announcements (prospectus supplements) that would signal immediate dilution. The effective shelf creates ongoing overhang; any offering below current market price would pressure the stock. Key catalyst remains the October 30, 2026 PDUFA date for INO-3107.

DirectionBearish
Confidencelow
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.16
T+0 close · Jul 13, 2026 · via day close
Latest settled
−2.59%
T+60 · $1.13
Vs SPY
−6.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $1.16entry
  2. T+1 · 4mo ago 0.00%α −0.36% · $1.16
  3. T+5 · 4mo ago −3.45%α −2.66% · $1.12
  4. T+20 · 3mo ago −36.52%α −39.70% · $0.7364
  5. T+60 · 6w ago −2.59%α −6.58% · $1.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company to raise up to $300M through sales of common stock, preferred stock, debt, or warrants. This formalizes the dilution overhang flagged in the prior S-3 analysis, as the company can now take down offerings at any time. Filing document content was unavailable, analysis based on metadata and cross-filing context only.

Key Facts

  • Shelf registration (S-3) declared effective, Inovio can now sell up to $300M in securities
  • Follows S-3 filed July 2, 2026; company has a history of frequent capital raises
  • Market cap is ~$97M, making potential dilution substantial relative to current equity value

Financial Impact

Up to $300M in potential capital raise, representing ~3x current market cap; dilution risk is material

dilutionshare countcash balance

Risk Factors

  • Imminent or gradual equity issuance diluting existing shareholders
  • Stock price pressure from overhang even without immediate takedown
  • Execution risk on pipeline development with limited cash runway

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026